Département de Néphrologie et Transplantation d'organes, Unité de Réanimation, Hôpital Rangueil, Centre Hospitalier Universitaire de Toulouse, 1, avenue Jean Poulhes, 31059, Toulouse, France.
Laboratoire d'Immunologie, Hôpital Rangueil, Centre Hospitalier Universitaire de Toulouse, F-31000, Toulouse, France.
BMC Anesthesiol. 2019 Jul 17;19(1):130. doi: 10.1186/s12871-019-0800-0.
Risk of over-immunosuppression or immunization may mitigate the overall and long-term renal outcomes of kidney transplant recipients (KTR) admitted to the ICU in the modern era but remain poorly described. Thus, there is an unmet need to better characterize the survival of KTR admitted to the ICU, but also the renal and immunological outcomes of survivors.
Retrospective observational study that included 200 KTR admitted between 2010 and 2016 to the ICU of a teaching hospital (median age 61 years [IQR 50.7-68]; time from transplantation 41 months [IQR 5-119]). Survival curves were compared using the Log-rank test.
Mortality rates following admission to the ICU was low (26.5% at month-6), mainly related to early mortality (20% in-hospital), and predicted by the severity of the acute condition (SAPS2 score) but also by Epstein Barr Virus proliferation in the weeks preceding the admission to the ICU. Acute kidney injury (AKI) was highly prevalent (85.1%). Progression toward chronic kidney disease (CKD) was observed in 45.1% of survivors. 15.1% of survivors developed new anti-HLA antibodies (donor-specific antibodies 9.2% of cases) that may impact the long-term renal transplantation function.
Notwithstanding the potential biases related to the retrospective and monocentric nature of this study, our findings obtained in a large cohort of KTR suggest that survival of KTR admitted in ICU is good but in-ICU management of these patients may alter both survival and AKI to CKD transition, as well as HLA immunization. Further interventional studies, including systematic characterization of the Epstein Barr virus proliferation at the admission (i.e., a potential surrogate marker of an underlying immune paralysis and frailty) will need to address the optimal management of immunosuppressive regimen in ICU to improve survival but also renal and immunological outcomes.
在现代,重症监护病房(ICU)收治的肾移植受者(KTR)过度免疫抑制或免疫接种的风险可能会改善其总体和长期肾脏预后,但目前对此描述仍不完善。因此,我们需要更好地描述 ICU 收治的 KTR 的生存率,还需要描述幸存者的肾脏和免疫结局。
这是一项回顾性观察性研究,纳入了 2010 年至 2016 年期间在教学医院 ICU 收治的 200 名 KTR(中位年龄 61 岁[IQR 50.7-68];移植后时间 41 个月[IQR 5-119])。使用对数秩检验比较生存曲线。
ICU 收治后的死亡率较低(6 个月时为 26.5%),主要与早期死亡率(住院期间 20%)相关,且与急性疾病严重程度(SAPS2 评分)以及 ICU 收治前数周内 Epstein Barr 病毒增殖相关。急性肾损伤(AKI)的发生率很高(85.1%)。幸存者中观察到慢性肾脏病(CKD)进展(45.1%)。15.1%的幸存者出现新的抗 HLA 抗体(供体特异性抗体占 9.2%),这可能会影响长期肾移植功能。
尽管这项研究存在回顾性和单中心的潜在偏倚,但我们在大型 KTR 队列中获得的研究结果表明,ICU 收治的 KTR 生存率良好,但 ICU 对这些患者的管理可能会改变患者的生存和 AKI 向 CKD 转变,以及 HLA 免疫。需要进一步的干预性研究,包括系统描述入院时 Epstein Barr 病毒增殖情况(即潜在的免疫麻痹和脆弱性替代标志物),以确定 ICU 中免疫抑制方案的最佳管理方法,以改善生存率,同时改善肾脏和免疫结局。